Page last updated: 2024-08-24

3-iodobenzylguanidine and End Stage Liver Disease

3-iodobenzylguanidine has been researched along with End Stage Liver Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fukuhara, E; Fukunami, M; Furukawa, Y; Hakui, H; Ikeda, I; Ishimi, M; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Kondo, T; Morita, T; Ozaki, T; Sakata, Y; Sato, Y; Seo, M; Tamaki, S; Yamada, T	1

Other Studies

1 other study(ies) available for 3-iodobenzylguanidine and End Stage Liver Disease

Article	Year
Usefulness of Cardiac MetaIodobenzylguanidine Imaging to Improve Prognostic Power of the Model for End-Stage Liver Disease Scoring System in Patients With Mild-to-Moderate Chronic Heart Failure. The American journal of cardiology, 2016, 06-15, Volume: 117, Issue:12 Topics: 3-Iodobenzylguanidine; End Stage Liver Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Severity of Illness Index; Time Factors; Ventricular Function, Left	2016

Article

Year

Usefulness of Cardiac MetaIodobenzylguanidine Imaging to Improve Prognostic Power of the Model for End-Stage Liver Disease Scoring System in Patients With Mild-to-Moderate Chronic Heart Failure.

The American journal of cardiology, 2016, 06-15, Volume: 117, Issue:12

Topics: 3-Iodobenzylguanidine; End Stage Liver Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Severity of Illness Index; Time Factors; Ventricular Function, Left

2016